Pre-Clinical Research
Filter News
Found 6,241 articles
-
CerSci Therapeutics Awarded Phase I STTR Grant From the National Institute of Neurological Disorders and Stroke of the National Institutes of Health to Test Feasibility of a New Therapeutic Approach to Treat Migraine
8/21/2018
CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas has received notice from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) that it has been awarded a Phase I Small Business Technology Transfer (STTR) grant totaling over $220,000. These funds will support the preclinical development of novel, proprietary small-molecules for the treatment of migraine.
-
IFM Therapeutics, LLC Presents Promising Preclinical Data for NLRP3 Inhibitors at ACS 2018
8/20/2018
Findings support continued development of small-molecule NLRP3 antagonists for treatment of inflammatory diseases
-
In the biotech world, only 7 to 9 percent of companies have women as their chief executives. Antiva BioSciences is a good example of how this problem is perpetuated.
-
Biohaven Pharma, headquartered in New Haven, Conn., announced positive data from a proof-of-concept trial for its BHV-0223 in social anxiety and public speaking anxiety disorders.
-
First Mouse Model to Mimic Lung Disease Could Speed Discovery of More Effective Treatments
8/16/2018
The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability to fully model the disease in animals, limiting the ability to observe and understand the disease.
-
Generally speaking, the larger the animal, the more cells they have, the more likely they are to get cancer. The longer an animal lives, even if that animal is a human being, the higher the likelihood of cancer. Except elephants. Elephants rarely get cancer.
-
CytoDyn Announces Strong Preclinical Results Using PRO 140 in Human Colon Carcinoma
8/15/2018
CytoDyn will file an IND, along with a proof-of-concept protocol for colon cancer
-
Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria
8/13/2018
Preclinical studies published in Nature Biotechnology identify key biomarkers of SYNB1618 activity in healthy animals and disease models
-
ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK
8/13/2018
Data Support ARQ 531 as a Potential First- and Best-In-Class Reversible BTK Inhibitor, with the Potential to Address Emerging Resistance to Irreversible BTK Inhibitors
-
NSW Health Funds Indee Labs’ First Preclinical Study Into Gene-Modified Cell Therapy Manufacturing for Blood Cancer
8/9/2018
This preclinical study will pave the way for biopharmaceutical companies to transition away from using viruses.
-
Ambys Medicines, based in Redwood City, California, has launched in an unusual deal with Osaka, Japan’s Takeda Pharmaceutical Company.
-
NanoViricides Reports Its Topical Dermal Shingles Candidates Effective in Reducing Pain in Animal Study
8/7/2018
NanoViricides, Inc. (NYSE Amer: NNVC) (the "Company") reports that its anti-Shingles drug candidates were effective in ameliorating pain sensations in an animal model of abnormal pain.
-
Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies
8/7/2018
Teneobio, Inc., a next generation multi-specific antibody therapeutics company, and Poseida Therapeutics, Inc., a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving cell therapies, announced today a new research collaboration and licensi... -
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter—basically a rejection—to Austin, Texas-based Pain Therapeutics for Remoxy ER for pain.
-
Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis
8/6/2018
Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's anti-fibrotic lead compound, PLN-74809, for the treatment of idiopathic pulmonary fibrosis (IPF).
-
Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease
8/6/2018
This pre-clinical study examines the Immunotoxicology and anti-inflammatory properties of GB Sciences' Cannabis-Containing Complex Formulas for Parkinson's Disease in preparation for their clinical trial.
-
Navitor Appoints New CEO
8/3/2018
Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer. -
Calculus Capital invests £2m in Oxford BioTherapeutics
8/3/2018
Calculus Capital, the award-winning Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist, has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments.
-
Mologic Commences Clinical Trial of Urine-Based Diagnostic for Cystic Fibrosis
8/2/2018
Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, today announced that it has commenced a clinical trial to evaluate the Company’s urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis (CF) patients.
-
Compugen Reports Second Quarter 2018 Results
8/1/2018
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2018.